About Acer Therapeutics
Acer Therapeutics is a Healthcare company based in Cambridge (United States) founded in 1991 by Chris Schelling, and was acquired by Zevra in November 2023. Treatments for ultra-rare diseases like vEDS and MSUD are developed. The company has 37 employees. Acer Therapeutics has completed 1 acquisition, including Opexa Therapeutics. Its chief executive, as recorded, is Chris Schelling. Acer Therapeutics offers products and services including OLPRUVA, EDSIVO, and Investigational Lifecycle Opportunities. Its focus areas include Life Sciences, Rare Diseases, Drugs and Metabolic Disorders. Its competitors include Alnylam, Ultragenyx and Gemini Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Acer Therapeutics is developing treatments for ultra-orphan diseases. Its drug portfolio includes ACER-002 for Vascular Ehlers-Danlos Syndrome (vEDS) for which Acer was awarded orphan drug designation by the FDA in January 2015and ACER-001 (orphan drug designation by the FDA in August 2014) for Maple Syrup Urine Disease (MSUD), EDS is a group of hereditary disorders of connective tissue and MSUD is a devastating genetic disease an inborn error of amino acid metabolism. ACER-001 is a reformulation of sodium phenylbutyrate (NaPBA) while Acer is repurposing celiprolol, a unique beta-blocker for the treatment of vEDS.
- Headquarters Cambridge, United States
- Employees 37
- Founders Chris Schelling
- Stage Acquired
- SectorsHealthcare
- Website acertx.com
- Social LinkedIn X Facebook
- Acquired by Zevra (Nov 2023)
Products & Services of Acer Therapeutics
Acer Therapeutics offers a comprehensive portfolio of products and services, including OLPRUVA, EDSIVO, and Investigational Lifecycle Opportunities.
Treatment for Maple Syrup Urine Disease conditions
Investigational treatment for Vascular Ehlers-Danlos Syndrome
Explores new therapies for ultra-rare diseases
Funding Insights of Acer Therapeutics
- Total Rounds 7
- Last Round Post-IPO β $1.5M
- First Round $2.1M
(Apr 2015)
- Investors Count 1
All 7 funding rounds of Acer Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2022 | $1.5M | Post-IPO | β | β | β |
| Jul 2020 | $857,493 | Post-IPO | β | β | β |
| Dec 2017 | $1.26M | Post-IPO | β | β | β |
| Oct 2017 | $15.67M | Post-IPO | β | β | β |
| Apr 2017 | $3.13M | Post-IPO | β | β | β |
| May 2016 | $8.15M | Post-IPO | β | β | |
| Apr 2015 | $2.1M | Post-IPO | β | β | β |
2 investors in total: 2 institutional.
Investors in Acer Therapeutics
Acer Therapeutics has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Zevra and TVM Capital Life Science.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Capital is invested in life science innovations for healthcare transformation. | tvm-capital.com | Munich, Germany | ||
Marketing services are provided to biopharma companies. | 2006 | zevra.com | Celebration, United States |
Investor details for Acer Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Acer Therapeutics
29 people are tracked at Acer Therapeutics (24 in leadership, 5 in team); the tracked headcount is 37.
| Name | Role | Group |
|---|---|---|
Chris Schelling | Founder & CEO | Leadership |
Lauren Hitchins | Director, Strategic Operations And Medical Excellence | Leadership |
David Rowe Wood | Head Of Field Medical Affairs | Leadership |
Adrian Quartel | Chief Medical Officer | Leadership |
Timothy Sangiovanni | Senior Vice President, Corporate Controller | Leadership |
Neil F. McFarlane | President and Chief Executive Officer | Leadership |
Rene A. Braeckman | Senior Vice President, Clinical Development | Leadership |
Laduane Clifton | Chief Financial Officer, Secretary And Treasurer | Leadership |
R. Laduane Clifton | Chief Financial Officer, Secretary, & Treasurer | Leadership |
Christopher M. Lauderback | Senior Vice President, Manufacturing | Leadership |
Adam Smith | Vice President, Business Development And Commercial Operations | Leadership |
Louise Himmelstrup | Vice President EU Regulatory Affairs | Leadership |
Sven Guenther | Chief Scientific Officer | Leadership |
Sanjib Bera | VP Drug Discovery | Leadership |
Abbi M. | Vp, Legal Affairs | Leadership |
Douglas Commerce | Sr. Director, CMC Quality Assurance | Leadership |
Tanya Hayden | Senior Vice President, Chief Of Staff | Leadership |
Mark Meier | Sr. Director, Marketing | Leadership |
Nichol Ochsner | Vice President, Investor Relations And Corporate Communications | Leadership |
Corinna Wetzel | Senior Director Product Development | Leadership |
9 more people are available in the full profile.
Complete people profiles for Acer Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Acer Therapeutics
Acer Therapeutics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Opexa Therapeutics.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Developing personalized T-cell therapies to treat autoimmune diseases, including multiple sclerosis. | opexatherapeutics.com | The Woodlands, United States | 2004 | Jul 2017 | β’β’β’β’ |
Complete acquisition details for Acer Therapeutics
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Acer Therapeutics
6 dated milestones of Acer Therapeutics across 32 years, from founding to its latest funding, stage changes and deals.
- Founded Acer Therapeutics is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $2.1M.
- Acquisition Acquires Opexa Therapeutics.
- Funding Latest funding round, Post-IPO, of $1.5M.
- Exit Acquired by Zevra.
Competitors of Acer Therapeutics
Acer Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Alnylam, Ultragenyx and Gemini Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| alnylam.com | 2002 | Cambridge, United States | $17M | 2,100 | RNA interference-based therapeutics are developed for multiple disorders. | |
| ultragenyx.com | 2010 | Novato, United States | $135.1M | 837 | Therapeutics for rare and ultra-rare metabolic diseases are developed. | |
| geminitherapeutics.com | 2015 | Cambridge, United States | $44.5M | 45 | Developer of precision therapeutics for dry AMD and rare genetic diseases |
Detailed competitors of Acer Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Rare Diseases
3 companies that operate in the same segment as Acer Therapeutics (Rare Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Acer Therapeutics
Complete news archive for Acer Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Acer Therapeutics
Acer Therapeutics was founded in 1991 and raised its 1st funding round 24 years after it was founded.
Acer Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Chris Schelling is the CEO of Acer Therapeutics, as recorded in our data. They have also founded this company.
Acer Therapeutics has 37 employees.
Annual revenue of Acer Therapeutics is $1.26M as on Dec 31, 2021.
Acer Therapeutics is developing treatments for ultra-orphan diseases. Its drug portfolio includes ACER-002 for Vascular Ehlers-Danlos Syndrome (vEDS) for which Acer was awarded orphan drug designation by the FDA in January 2015and ACER-001 (orphan drug designation by the FDA in August 2014) for Maple Syrup Urine Disease (MSUD), EDS is a group of hereditary disorders of connective tissue and MSUD is a devastating genetic disease an inborn error of amino acid metabolism. ACER-001 is a reformulation of sodium phenylbutyrate (NaPBA) while Acer is repurposing celiprolol, a unique beta-blocker for the treatment of vEDS.
Acer Therapeutics's top competitors include Alnylam, Ultragenyx and Gemini Therapeutics.
Acer Therapeutics offers OLPRUVA, EDSIVO, and Investigational Lifecycle Opportunities.
Acer Therapeutics has made 1 acquisition, including Opexa Therapeutics.
Acer Therapeutics has 2 investors. Key investors include Zevra, and TVM Capital Life Science.
Yes. Acer Therapeutics was acquired by Zevra in November 2023.

